Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

¹⁸F-FDG PET/CT in HIV-related central nervous system pathology.

Lewitschnig S, Gedela K, Toby M, Kulasegaram R, Nelson M, O'Doherty M, Cook GJ.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1420-7. doi: 10.1007/s00259-013-2448-1. Epub 2013 May 18.

PMID:
23685752
2.

Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.

Westwood TD, Hogan C, Julyan PJ, Coutts G, Bonington S, Carrington B, Taylor B, Khoo S, Bonington A.

Eur J Radiol. 2013 Aug;82(8):e374-9. doi: 10.1016/j.ejrad.2013.03.008. Epub 2013 Apr 8.

PMID:
23578921
3.

Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.

Manohar K, Bhattacharya A, Mittal BR.

Nucl Med Commun. 2013 Jun;34(6):540-3. doi: 10.1097/MNM.0b013e32836066c0.

PMID:
23503001
4.

Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.

Zhou WL, Wu HB, Wang LJ, Tian Y, Dong Y, Wang QS.

Eur J Radiol. 2016 Jan;85(1):205-210. doi: 10.1016/j.ejrad.2015.11.019. Epub 2015 Nov 28.

PMID:
26724667
5.

Prospective comparison of whole-body (18)F-FDG PET/CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis.

Fuster D, Tomás X, Mayoral M, Soriano A, Manchón F, Cardenal C, Monegal A, Granados U, Garcia S, Pons F.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):264-71. doi: 10.1007/s00259-014-2898-0. Epub 2014 Sep 4.

PMID:
25186431
6.

Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.

Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J, Umutlu L, Antoch G, Kinner S.

Eur J Radiol. 2016 Feb;85(2):459-65. doi: 10.1016/j.ejrad.2015.12.010. Epub 2015 Dec 19.

PMID:
26781152
7.

Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry.

Mhlanga JC, Durand D, Tsai HL, Durand CM, Leal JP, Wang H, Moore R, Wahl RL.

Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):596-604. doi: 10.1007/s00259-013-2671-9. Epub 2014 Jan 28.

8.

Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.

Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS, Ahn SH, Lee JW, Son BH, Gong GY, Moon DH.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):438-45. doi: 10.1007/s00259-013-2600-y. Epub 2013 Nov 6.

PMID:
24196918
9.

(18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.

Asabella AN, Cimmino A, Altini C, Notaristefano A, Rubini G.

Hell J Nucl Med. 2011 Sep-Dec;14(3):311-2.

PMID:
22087457
10.

Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.

Povoski SP, Hall NC, Murrey DA Jr, Wright CL, Martin EW Jr.

BMC Cancer. 2015 May 8;15:378. doi: 10.1186/s12885-015-1381-z.

11.

18F-FDG PET/CT in patients with adult-onset Still's disease.

Dong MJ, Wang CQ, Zhao K, Wang GL, Sun ML, Liu ZF, Xu L.

Clin Rheumatol. 2015 Dec;34(12):2047-56. doi: 10.1007/s10067-015-2901-6. Epub 2015 Feb 26.

PMID:
25711875
12.

PET scanning and the human immunodeficiency virus-positive patient.

O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS.

J Nucl Med. 1997 Oct;38(10):1575-83.

13.

18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.

Giraudo C, Raderer M, Karanikas G, Weber M, Kiesewetter B, Dolak W, Simonitsch-Klupp I, Mayerhoefer ME.

Invest Radiol. 2016 Mar;51(3):163-9. doi: 10.1097/RLI.0000000000000218.

14.

Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.

Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G.

Nucl Med Commun. 2011 Dec;32(12):1162-8. doi: 10.1097/MNM.0b013e32834bbe09.

PMID:
21946617
15.
16.

Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.

Nakajo M, Nakajo M, Kajiya Y, Jinguji M, Nishimata N, Shimaoka S, Nihara T, Aridome K, Tanaka S, Fukukura Y, Tani A, Koriyama C.

Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1223-32. doi: 10.1007/s00259-013-2424-9. Epub 2013 May 8.

PMID:
23653240
17.

Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma.

Wang LJ, Wu HB, Wang M, Han YJ, Li HS, Zhou WL, Wang QS.

Eur J Radiol. 2015 Nov;84(11):2275-9. doi: 10.1016/j.ejrad.2015.09.011. Epub 2015 Sep 11.

PMID:
26388466
18.

Incidental colonic focal FDG uptake on PET/CT: can the maximum standardized uptake value (SUVmax) guide us in the timing of colonoscopy?

van Hoeij FB, Keijsers RG, Loffeld BC, Dun G, Stadhouders PH, Weusten BL.

Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):66-71. doi: 10.1007/s00259-014-2887-3. Epub 2014 Aug 20.

PMID:
25139518
19.

Utility of 18F-FDG PET/CT in the diagnosis and staging of extramammary Paget's disease.

Tian Y, Wu HB, Li DL, Li HS, Zhou WL, Wang QS.

Nucl Med Commun. 2015 Sep;36(9):892-7. doi: 10.1097/MNM.0000000000000340.

PMID:
25932540
20.

(18)F-FDG PET-CT: a powerful tool for the diagnosis and treatment of relapsing polychondritis.

Lei W, Zeng H, Zeng DX, Zhang B, Zhu YH, Jiang JH, Huang JA.

Br J Radiol. 2016;89(1057):20150695. doi: 10.1259/bjr.20150695. Epub 2015 Nov 3.

Supplemental Content

Support Center